A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE

BACKGROUND: Biologic therapy has revolutionized inflammatory bowel disease (IBD) care. More recently, newer biologics have been approved. Despite multiple options, clinical remission rates at one year are approximately 40% for any single biologic agent. In addition, questions surround the efficacy o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Panaccione, N, Novak, K L, Seow, C, Devlin, S, Lu, C, Heatherington, J, Kaplan, G G, Panaccione, R
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Posters Of Distinction
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512451/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados